2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)

Purpose

The Investigators will test the hypothesis that 2-HOBA will reduce modification of HDL and LDL and improve HDL function in humans with heterozygous FH. The Investigators plan to first study subjects with Familial Hypercholesterolemia (FH), treating them with 750 mg of 2-HOBA or placebo every 8 hours for 6 weeks.

Condition

  • Familial Hypercholesterolemia

Eligibility

Eligible Ages
Between 18 Years and 69 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Individuals with heterozygous Familial Hypercholesterolemia.

Exclusion Criteria

  • Myocardial infarction or stroke within the last 6 months - unstable angina, symptoms of angina within the last 3 months - NYHA class III or IV heart failure or LVEF < 30% - poorly controlled hypertension: SBP > 180 mm Hg or DBP > 110 mm Hg, - pregnancy, - evidence of a previous acute coronary syndrome, - current smokers, - individuals with Type 2 Diabetes Mellitus, obesity (BMI > 30), - hypertriglyceridemia (fasting TG > 250 mg/dl), - renal insufficiency (Cr > 1.8), - hepatic disease (aspartate aminotransferase(AST) or alanine aminotransferase (ALT) > 2x ULN), - hypothyroidism, - nephrotic syndrome, - rheumatoid arthritis, - systemic lupus erythematosus, - AIDS or HIV - history of malignancy of any organ in last 5 years.

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Prevention
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Active Comparator
2-Hydroxybenzylamine (2-HOBA)
2-Hydroxybenzylamine (2-HOBA) 250 mg three tabs TID (po) for 6 weeks.
  • Drug: 2-Hydroxybenzylamine
    2-Hydroxybenzylamine (2-HOBA) 250 mg three tabs TID (po) for 6 weeks.
    Other names:
    • 2-HOBA
Placebo Comparator
Placebo
Placebo- three tabs TID (po) for 6 weeks.
  • Other: Placebo
    Placebo 250 mg three tabs TID (po) for 6 weeks.

Recruiting Locations

Vanderbilt University Medical Center
Nashville, Tennessee 37212

More Details

Status
Recruiting
Sponsor
Vanderbilt University Medical Center

Study Contact

Anca Ifrim, RN
6155224210
anca.ifrim@vumc.org